Health & Nutrition

Themenbereich / / Health & Nutrition


Sortiere PresseMitteilungen nach: Titel (A\D) Datum (A\D)

Seiten sind aktuell sortiert nach: Datum (erst neue PresseMitteilungen)

IntelGenx Submits Montelukast VersaFilm(TM) Clinical Trial Application With Health Canada

SAINT-LAURENT, QUEBEC -- (Marketwired) -- 11/09/17 -- IntelGenx Corp. (TSX VENTURE: IGX)(OTCQX: IGXT) (the "Company" or "IntelGenx"), today announced that it has submitted a clinical trial application ("CTA") to Health Canada for approval to initiate its Phase 2a proof of concept ("POC") study with Montelukast in mild to moderate Alzheimer''s Disease ("AD").The study, entitled "A randomized Phase IIa, multi-center, double-blind, placebo-controlled study to assess the safety, feasibility, tolerability, and efficacy of a new bucc ...

09.11.2017

IntelGenx Reports Third Quarter 2017 Financial Results

SAINT-LAURENT, QUEBEC -- (Marketwired) -- 11/09/17 -- IntelGenx Technologies Corp. (TSX VENTURE: IGX)(OTCQX: IGXT) (the "Company" or "IntelGenx") today reported financial results for the third quarter ended September 30, 2017. All dollar amounts are expressed in U.S. currency and results are reported in accordance with United States generally accepted accounting principles except where noted otherwise.2017 Third Quarter Financial Highlights:Recent Developments:"With the completion of convertible debenture offering during the third quarter, we secured the necessary fi ...

09.11.2017

Nephros Reports Third Quarter 2017 Financial Results

RIVER EDGE, NJ -- (Marketwired) -- 11/09/17 -- Nephros, Inc. (OTCQB: NEPH) (the "Company"), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis (HD) machine for the treatment of patients with End Stage Renal Disease (ESRD), today announced financial results for the three months ended September 30, 2017."Our 93% year-over-year revenue growth in the third quarter suggests that our focus on an expanded product portfolio and strategic dist ...

09.11.2017

Nephros Announces Approval of $1.9 Million in NJEDA NOL Program Tax Credits

RIVER EDGE, NJ -- (Marketwired) -- 11/06/17 -- Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis (HD) machine for the treatment of patients with End Stage Renal Disease (ESRD), announced today the receipt of $1.9 million in tax credit certificates from New Jersey Economic Development Authority (NJEDA), which are expected be sold later this quarter for over $1.75 million in net proceeds.Nephros received the tax credit ce ...

06.11.2017

IntelGenx to Report Third Quarter 2017 Financial Results on November 9, 2017 - Conference Call to Follow

SAINT-LAURENT, QUEBEC -- (Marketwired) -- 11/02/17 -- IntelGenx Technologies Corp., (TSX VENTURE: IGX)(OTCQX: IGXT), today announced that it will release its third quarter 2017 financial results after market close on November 9, 2017.An accompanying conference call will be hosted by Dr. Horst G. Zerbe, President and Chief Executive Officer, and Mr. Andre Godin, Executive Vice-President and Chief Financial Officer, to discuss the results and provide a business update. Details of the conference call and webcast are below:Webcast Registration:Following the live call, a replay will be available o ...

02.11.2017

Tauriga Sciences, Inc. Confirms Canadian Trading Halt Lifted at Open of Market on November 1, 2017

NEW YORK, NY -- (Marketwired) -- 11/01/17 -- Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"), a company engaged in building businesses in the life sciences space, today announced that the Autorité des Marchés Financiers (the "AMF") provided the Company written notification on October 31, 2017 that the AMF has lifted the Canadian Cease Trade Order ("Trading Halt"). Trading in the Company''s securities for its Canadian-based shareholders will commence at market open Wednesday, November 1, 2017.The Trading Halt was initially ...

01.11.2017

IntelGenx and RedHill Biopharma Resubmit RIZAPORT® New Drug Application to the FDA

SAINT LAURENT, QUEBEC -- (Marketwired) -- 11/01/17 -- IntelGenx Corp. (TSX VENTURE: IGX)(OTCQX: IGXT) ("IntelGenx"), a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform, together with RedHill Biopharma Ltd. (NASDAQ: RDHL)(TASE: RDHL) ("RedHill"), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal ...

01.11.2017

Nephros Provides Corporate Update and Announces Preliminary Third Quarter 2017 Revenue

RIVER EDGE, NJ -- (Marketwired) -- 10/16/17 -- Nephros, Inc. (OTCQB: NEPH) (the "Company"), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis (HD) machine for the treatment of patients with End Stage Renal Disease (ESRD), is providing a general update on the Company''s activities and guidance for the third quarter of 2017.HydraGuard™ and EndoPur™ UltrafiltersThe Company has begun selling all versions of the EndoPur™ and HydraGua ...

16.10.2017

Tauriga Sciences, Inc. & Ice + Jam LLC Confirm Timing for Formal Launch of Proprietary Cupuacu Butter Lip Balm Product to the Retail Marketplace

NEW YORK, NY -- (Marketwired) -- 10/12/17 -- Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"), engaged in the building of life sciences businesses and technologies, today announced with its licensor Ice + Jam LLC ("Ice + Jam"), that the Companies have selected the week of December 17, 2017 for the formal launch of "HerMan" branded product; a proprietary cupuacu butter lip balm product packaged in the industry standard cylindrical tube. The two Companies have previously announced that the label and graphics were redesigned and improve ...

12.10.2017

Plastic Surgeon in Fort Worth Highlights What to Expect During Rhinoplasty Recovery

FORT WORTH, TX -- (Marketwired) -- 10/12/17 -- Often referred to as a "nose job," is a surgical procedure performed to improve the shape of the nose and/or correct nasal breathing issues. According to Fort Worth plastic surgeon Jon Kurkjian, MD, treatment can be custom-tailored to address the nasal tip, bridge, nostrils, and/or issues involving internal structure, such as a deviated septum. When performed safely and skillfully, the final result can be a nose that functions properly and blends harmoniously with the rest of one''s facial features.As with most plastic surger ...

12.10.2017

Tauriga Sciences, Inc. Fully Repays $45,000 USD Face Value Convertible Debenture for One-Time Cash Payment of $72,457.89 USD & Conditional Deferred Issuance of 10,000,000 Shares

NEW YORK, NY -- (Marketwired) -- 10/11/17 -- Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"), engaged in building businesses in the life sciences space, today announced that is has fully repaid and retired a $45,000 face value 12% convertible debenture (the "Note") held by Group 10 Holdings, LLC ("Group 10"). This convertible debenture, which was issued by the Company on November 7, 2016 and was due on November 8, 2017, has been fully repaid for a one-time cash payment of $72,457.89 received by Group 10 on October 10, 2017. Accordin ...

11.10.2017

Corix Bioscience Inc. to Purchase 46,060 Square Foot Research Facility

PHOENIX, AZ -- (Marketwired) -- 10/05/17 -- Corix Bioscience Inc. (OTCQB: CXBS) has entered into a contract to purchase a 46,060 square foot building in Carson City, Nevada. Closing is expected to occur on or before November 4, 2017. Purchase price for the building was finalized at $1,300,000.The building will serve as Corix Bioscience''s new research and development laboratory with an indoor grow facility specifically for their industrial hemp genetics. Genetics of industrial hemp and cannabis is the core of Corix''s business.Michael Ogburn, CEO of Corix Bioscience, state ...

05.10.2017

Skinvisible and Canopy Growth Enter License Agreement

SMITH FALLS, ON and LAS VEGAS, NV -- (Marketwired) -- 09/28/17 -- Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) and Skinvisible Pharmaceuticals, Inc. ("Skinvisible") (OTCQB: SKVI), a research and development company with a patented drug delivery system, today announce they have signed a definitive license agreement for Skinvisible''s patented topical formulations. Per the agreement, Canopy Growth is exclusively licensed to distribute Skinvisible''s topical products in Canada, and shall have a first right of refusal f ...

28.09.2017

Sipp Industries Signs Definitive Agreement to Acquire Minority Stake in Wanderport Corporation, Jointly Introduces New Hemp Beer

COSTA MESA, CA -- (Marketwired) -- 09/26/17 -- Sipp Industries, Inc. (OTC: SIPC), a multifaceted corporation specializing in technology, manufacturing, and distribution of commercial and consumer products is pleased to announce that the Company has signed the definitive agreement to acquire a minority stake of Wanderport Corporation (OTC: WDRP) via a stock swap.Per the terms of the agreement, the Company will receive twenty five million restricted common shares of Wanderport Corporation in exchange for twenty five million restricted common shares of Sipp Industries."We are a strong belie ...

26.09.2017

IntelGenx Announces Decisions in Suboxone(R) Patent Litigation

SAINT-LAURENT, QUEBEC -- (Marketwired) -- 09/06/17 -- IntelGenx Corp. (TSX VENTURE: IGX)(OTCQX: IGXT) ("IntelGenx" or the "Company") today announced that the U.S. District Court for the District of Delaware (the "Delaware Court"), in a decision rendered August 31, 2017, determined that the process used to manufacture IntelGenx'' and Par Pharmaceutical, Inc.''s ("Par") buprenorphine/naloxone sublingual film product for the treatment of opiate addiction does not infringe MonoSol Rx U.S. Patent No. 8,900,497 (the "497 patent" ...

06.09.2017

Tauriga Sciences, Inc. Taking Immediate and Concrete Steps to Extinguish the Canadian Cease Trade Order Instituted by AUTORITE DES MARCHES FINANCIERS (Quebec Based Regulatory Authority)

NEW YORK, NY -- (Marketwired) -- 09/06/17 -- Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"), a company engaged in building businesses in the life sciences space, today announced that it is taking immediate and concrete steps to extinguish the Canadian Cease Trade Order ("trading halt") that was instituted by AUTORITE DES MARCHES FINANCIERS ("AMF") on August 6, 2015. This Canadian trading halt was a direct result of the Company''s inability to file its Fiscal Year 2015 Form 10-K during July 2015. Additionally, the Company ...

06.09.2017

IntelGenx Grants Stock Options

SAINT LAURENT, QUEBEC -- (Marketwired) -- 08/31/17 -- IntelGenx Technologies Corp. ("IntelGenx", or the "Company") (TSX VENTURE: IGX)(OTCQX: IGXT) announced today that the Company''s board of directors granted options to acquire a total of 359,818 common shares under the 2016 Stock Option Plan.Of the total stock options granted, 179,908 were granted to the Horst G. Zerbe, Chief Executive Officer and President and 59,970 were granted to Andre Godin, Executive Vice President and Chief Financial Officer. Furthermore, 59,970 stock options were granted to each of two ...

31.08.2017

IntelGenx to Present at the 19th Annual Rodman & Renshaw Global Investment Conference

SAINT-LAURENT, QUEBEC -- (Marketwired) -- 08/30/17 -- IntelGenx Technologies Corp., (TSX VENTURE: IGX)(OTCQX: IGXT), today announced that its President and Chief Executive Officer, Dr. Horst Zerbe, is scheduled to present at the Rodman & Renshaw 19th Annual Global Investment Conference on Monday, September 11 at 12:30 p.m. Eastern Time at the at the Lotte New York Palace Hotel.Dr. Zerbe will provide an overview of IntelGenx'' business during the presentation and, along with Andre Godin, Executive Vice-President and Chief Financial Officer, will be available to participate in on ...

30.08.2017

Tauriga Sciences, Inc. Fully Retires $104,000 7.00% USD Convertible Debenture Issued to Union Capital LLC on May 28, 2015

NEW YORK, NY -- (Marketwired) -- 08/30/17 -- Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"), a company engaged in building businesses in the life sciences space, today announced that it has retired the $104,000 USD 7.00% convertible debenture (the "Note") held by Union Capital, LLC ("Union Capital" or "Lender"). This Note was issued by the Company on May 28, 2015. Accordingly, this debt will be removed from the Company''s balance sheet.This Note was retired exclusively through conversions (13 distinct conversion ...

30.08.2017

UPDATE - Letter from BioElectronics'' (OTC PINK: BIEL) President to Investors

FREDERICK, MD -- (Marketwired) -- 08/29/17 -- The following is a statement from BioElectronics (OTC PINK: BIEL).Dear Fellow Shareholders,These are busy and exciting times at BioElectronics.Over the last few years, there have been two significant developments: 1) There has been a paradigm shift in the medical community''s understanding of how chronic pain develops, and 2) There is evidence that BioElectronics'' technology platform (Pulsed Shortwave Therapy) works by regulating the activity of nerves in the body, i.e. by neuromodulation. Together they present an excellent op ...

29.08.2017


Page 1 from 94:  1 2  3  4  5  .. » 94





All members: 8 020
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 45


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.